程序性细胞死亡受体-1/程序性细胞死亡受体配体-1抑制剂治疗结直肠癌的研究进展

Research advances of PD-1/PD-L1 inhibitors in the treatment of colorectal cancer

程序性细胞死亡受体-1(programmed cell death-1, PD-1)/程序性细胞死亡受体配体-1(programmed cell death-ligand 1, PD-L1)信号通路是诱导肿瘤免疫逃逸的主要机制,在肿瘤形成中起着免疫检查点的作用。近年来,随着抗PD-1/PD-L1单克隆抗体成功地用于治疗黑素瘤、肾细胞癌、膀胱癌和非小细胞肺癌,PD-1/PD-L1抑制剂已成为实体瘤免疫治疗研究中的热点之一。本文概要介绍PD-1/PD-L1抑制剂用于结直肠癌免疫治疗的研究进展。

Programmed cell death-1(PD-1)/programmed cell death-ligand 1(PD-L1) signaling pathway is the main mechanism of inducing tumor immune escape and plays the role of immune checkpoint in tumor formation. With the successful development of monoclonal antibodies against PD-1/PD-L1 in melanoma, renal cell carcinoma, bladder cancer and non-small cell lung cancer, PD-1/PD-L1 inhibitors have become a research hotspot in solid tumor immunotherapy. In this review, we present a comprehensive knowledge of immunotherapy through PD-1/PD-L1 blockade and review the related research advances in colorectal cancer.